3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
32
Tumor-Agnostic
7
Gastrointestinal
6
CNS
6
Lymphoid
4
Genitourinary
4
Sarcoma
3
Other hematologic neoplasm
3
Breast
3
Head & Neck
2
Gynecologic
2
Endocrine
2
Other solid neoplasm
1
NET
1
Dermatologic
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
326
Nivolumab
289
Ipilimumab
260
Cyclophosphamide
193
aldesleukin
145
Interleukin-2
109
fludarabine phosphate
106
Temozolomide
83
Dacarbazine
81
fludarabine
80
Radiotherapy
74
trametinib
73
Vemurafenib
69
dabrafenib
66
Biopsy
65
sargramostim
50
Bevacizumab
50
Radiosurgery
49
Paclitaxel
49
Peripheral Blood Stem Cell Transplantation
48
Carboplatin
48
Magnetic Resonance Spectroscopy
47
Imiquimod
47
Aminolevulinic Acid
47
binimetinib
45
Cisplatin
45
CTLA-4 Antigen
43
cemiplimab
42
atezolizumab
41
Specimen Handling
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
alectinib
×
Dermatologic
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts